Nantong Jinghua Pharmaceutical Co Ltd (002349) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Nantong Jinghua Pharmaceutical Co Ltd (002349) has a cash flow conversion efficiency ratio of 0.032x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥97.93 Million ≈ $14.33 Million USD) by net assets (CN¥3.09 Billion ≈ $452.80 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Nantong Jinghua Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2006–2024)
This chart illustrates how Nantong Jinghua Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 002349 total liabilities for a breakdown of total debt and financial obligations.
Nantong Jinghua Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nantong Jinghua Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Friend Co Ltd
SHG:605050
|
N/A |
|
Joeone Co Ltd
SHG:601566
|
0.013x |
|
Tianjin Printronics Circuit Corp
SHE:002134
|
0.067x |
|
Astra Agro Lestari Tbk
JK:AALI
|
0.063x |
|
Shenzhen Bingchuan Network Co Ltd
SHE:300533
|
0.009x |
|
EQ Resources Ltd
AU:EQR
|
-0.169x |
|
Sdiptech AB (publ)
ST:SDIP-B
|
0.080x |
|
Neto Malinda
TA:NTML
|
-0.058x |
Annual Cash Flow Conversion Efficiency for Nantong Jinghua Pharmaceutical Co Ltd (2006–2024)
The table below shows the annual cash flow conversion efficiency of Nantong Jinghua Pharmaceutical Co Ltd from 2006 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Nantong Jinghua Pharmaceutical Co Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥2.96 Billion ≈ $432.72 Million |
CN¥311.02 Million ≈ $45.51 Million |
0.105x | +1.25% |
| 2023-12-31 | CN¥2.80 Billion ≈ $410.35 Million |
CN¥291.31 Million ≈ $42.63 Million |
0.104x | -23.95% |
| 2022-12-31 | CN¥2.62 Billion ≈ $383.94 Million |
CN¥358.39 Million ≈ $52.44 Million |
0.137x | +14.86% |
| 2021-12-31 | CN¥2.57 Billion ≈ $376.01 Million |
CN¥305.57 Million ≈ $44.71 Million |
0.119x | -9.90% |
| 2020-12-31 | CN¥2.49 Billion ≈ $363.89 Million |
CN¥328.22 Million ≈ $48.03 Million |
0.132x | -0.67% |
| 2019-12-31 | CN¥2.15 Billion ≈ $314.28 Million |
CN¥285.38 Million ≈ $41.76 Million |
0.133x | +329.14% |
| 2018-12-31 | CN¥2.69 Billion ≈ $394.28 Million |
CN¥83.43 Million ≈ $12.21 Million |
0.031x | +7.96% |
| 2017-12-31 | CN¥2.65 Billion ≈ $387.36 Million |
CN¥75.92 Million ≈ $11.11 Million |
0.029x | -80.79% |
| 2016-12-31 | CN¥2.30 Billion ≈ $336.95 Million |
CN¥343.80 Million ≈ $50.31 Million |
0.149x | +538.78% |
| 2015-12-31 | CN¥2.23 Billion ≈ $326.88 Million |
CN¥-76.01 Million ≈ $-11.12 Million |
-0.034x | -214.26% |
| 2014-12-31 | CN¥1.53 Billion ≈ $224.56 Million |
CN¥45.70 Million ≈ $6.69 Million |
0.030x | +140.21% |
| 2013-12-31 | CN¥741.83 Million ≈ $108.55 Million |
CN¥-54.94 Million ≈ $-8.04 Million |
-0.074x | -168.54% |
| 2012-12-31 | CN¥714.87 Million ≈ $104.61 Million |
CN¥77.25 Million ≈ $11.30 Million |
0.108x | +65.90% |
| 2011-12-31 | CN¥636.30 Million ≈ $93.11 Million |
CN¥41.45 Million ≈ $6.06 Million |
0.065x | -13.63% |
| 2010-12-31 | CN¥544.45 Million ≈ $79.67 Million |
CN¥41.06 Million ≈ $6.01 Million |
0.075x | -82.10% |
| 2009-12-31 | CN¥137.11 Million ≈ $20.06 Million |
CN¥57.76 Million ≈ $8.45 Million |
0.421x | +191.81% |
| 2008-12-31 | CN¥118.66 Million ≈ $17.36 Million |
CN¥17.13 Million ≈ $2.51 Million |
0.144x | -60.84% |
| 2007-12-31 | CN¥91.86 Million ≈ $13.44 Million |
CN¥33.86 Million ≈ $4.96 Million |
0.369x | +16.34% |
| 2006-12-31 | CN¥70.00 Million ≈ $10.24 Million |
CN¥22.18 Million ≈ $3.25 Million |
0.317x | -- |
About Nantong Jinghua Pharmaceutical Co Ltd
Jinghua Pharmaceutical Group Co., Ltd. engages in the research and development, manufacture, and sale of APIs and pharmaceutical intermediates in China. Its primary products include Phenobarbital, Primidone, Fluorouracil, Phenylbutazone, Flucytosine, Piroxicam, and Propylthiouracil APIs. The company was formerly known as Nantong Jinghua Pharmaceutical Co., Ltd. The company was founded in 1957 and… Read more